Understanding COPD Pathophysiology

Real-Time Live Broadcast

Keith Varnes, RRT-ACCS, RRT-NPS, AE-C

Rebecca Hudgins, BSRC, RRT

This Presentation is Approved for
1 CRCE Credit Hour

Learning Objectives

- **Define COPD.**
- **Describe chronic bronchitis & emphysema.**
- **Identify risk factors & etiology.**
- **Identify strategies for prevention.**
- **Outline appropriate treatment options.**

COPD

Chronic Obstructive Pulmonary Disease (COPD) is a **heterogeneous** lung condition characterized by **chronic** respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to **abnormalities of the airways** (bronchitis, bronchiolitis) **and/or alveoli** (emphysema) that cause persistent, often **progressive**, airflow obstruction.

(Original) Source: Celli, et al. Am J Respir Crit Care Med 2022

Bernoulli Principle



Bernoulli Principle



Chronic Bronchitis



Chronic Bronchitis



https://www.ncbi.nlm.nih.gov/books/NBK482437/

Reid Index


Basement membrane
Mucous glands
Mucous lining
Chronic inflammatory cell infiltrate
↑Mucous glands
Goblet cell hyperplasia
B
A
Cartilage
Reid index=Ratio of B:A
Reid index increased
NORMAL
CHRONIC BRONCHITIS

Emphysema


Normal bronchiole and alveoli
Alveoil affected by emphysema

Smoking

Neutrophils

Elastase

Alpha1 Anti-Trypsin

Asthma vs Emphysema

PRIMARY CELL TYPES

Asthma

- CD4 T-cells
- Eosinophils
- Plasma cells
- Mast cells

COPD

- Macrophages
- Neutrophils
- CD8 T- cells

Asthma vs Emphysema

KEY MEDIATORS

Asthma

- IL-4
- IL-5
- IL-13

COPD

- IL-8
- TNF-alpha

Asthma vs Emphysema

PRIMARY INFLAMMATION SITE

Asthma

- Proximal airways

COPD

- Distal airways
- Lung parenchyma

Risk Factors

Smoking

Pollution

Genetics

Etiotypes For COPD

GOLD Definition

- COPD C- Cigarette Smoking (Vaping & Cannabis)

~Including Passive and In Utero

- COPD P- Pollution Exposure

~ Wildfire Smoke, Occupational Hazards, Air Pollution

- COPD G- Genetically determined

~ Alpha 1 Trypsin Deficiency (other genetic variants)

Etiotypes For COPD

GOLD Definition Cont.

- COPD D- Abnormal Lung Development

~ Early Life Events, Premature and Low Birth Weight

- COPD I- Infections

~ Childhood Infections, Tuberculosis associated COPD, HIV associated COPD

- COPD A- Asthma

~Develops from childhood asthma

- COPD U- Unknown causes

Boyle's Law

P1V1 = P2V2.



Diagnosis of COPD

- **Evaluate Symptoms**

- **History of Risk Factors**
- **Persistent dyspnea that worsens with exercise**
- **Recurrent Wheeze**
- **Chronic Cough**
- **Recurrent respiratory infections**

Pink Puffer VS Blue Bloater

- Thin, pink skin
- Pursed Lip Breathing
- Dyspnea
- Minimal Cough
- Accessory Muscle Use
- Hyperinflation
- Barrel Chest
- Decreased Breath Sounds
- Tachypnea

**Pneumothorax (due to blebs)

- Obese
- Cyanotic
- Chronic, Productive Cough
- Digital Clubbing
- Crackles and Wheezes
- Purulent Sputum
- Peripheral Edema
- Prolonged Exhalation

** Polycythemia

Scoring



COPD FOUNDATION

This survey asks questions about you, your breathing and what you are able to do. To complete the survey, mark an X in the box that best describes your answer for each question below.

1. During the past 4 weeks, how much of the time did you feel short of breath?

None of the time	A little of the time	Some of the time	Most of the time	All of the time
☐ 0	☐ 0	☐ 1	☐ 2	☐ 2

2. Do you ever cough up any "stuff," such as mucus or phlegm?

No, never	Only with occasional colds or chest infections	Yes, a few days a month	Yes, most days a week	Yes, every day
☐ 0	☐ 0	☐ 1	☐ 1	☐ 2

3. Please select the answer that best describes you in the past 12 months. I do less than I used to because of my breathing problems.

Strongly disagree	Disagree	Unsure	Agree	Strongly agree
☐ 0	☐ 0	☐ 0	☐ 1	☐ 2

4. Have you smoked at least 100 cigarettes in your ENTIRE LIFE?

No	Yes	Don't know
☐ 0	☐ 2	☐ 0

5. How old are you?

Age 35 to 49	Age 50 to 59	Age 60 to 69	Age 70+
☐ 0	☐ 1	☐ 2	☐ 2

How to Score Your Screener: In the spaces below, write the number that is next to your answer for each of the questions. Add the number to get the total score. The total score can range from 0 to 10.

____ (#1) + ____ (#2) + ____ (#3) + ____ (#4) + ____ (#5) = _____ TOTAL SCORE

If your total score is 5 or more, this means your breathing problems may be caused by chronic obstructive pulmonary disease (COPD). The higher your score, the more likely you are to have COPD. COPD is often referred to as chronic bronchitis and/or emphysema and is a serious lung disease that slowly gets worse over time. While COPD cannot be cured, it is treatable, so please share your answers to the five question screener with your healthcare professional (HCP).

If your total score is between 0 and 4, and you are experiencing problems with your breathing, please share your answers to the five-question screener with your HCP.

Only your HCP can decide if you have COPD. Your HCP can help evaluate your breathing problems by performing a breathing test, also known as spirometry. Don't wait. Call your HCP today to make an appointment to see if you may be at risk for COPD. Remember, when speaking to your HCP, be honest and open in describing your symptoms and explain how your breathing problems affect your activity level on a daily basis.

Questionnaires

- **CAT**
- **MRC**

Modified MRC Dyspnea Scale

Figure 2.8

PLEASE TICK IN THE BOX THAT APPLIES TO YOU | ONE BOX ONLY | Grades 0 - 4

mMRC Grade 0	mMRC Grade 1	mMRC Grade 2	mMRC Grade 3	mMRC Grade 4
I only get breathless with strenuous exercise	I get short of breath when hurrying on the level or walking up a slight hill	I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level	I stop for breath after walking about 100 meters or after a few minutes on the level	I am too breathless to leave the house or I am breathless when dressing or undressing
☐	☐	☐	☐	☐

Reference: ATS (1982) Am Rev Respir Dis. Nov;126(5):952-6.

CRJ2

Spirometry: Obstructive Disease



Slide 22

CRJ2 Sue i have inserted a bracket and shifted the obstructive label. The FVC in this slide is about 3.4 by eyeball - shoudl be moved down to 3.2 or the numbers should be changed

Christine Jenkins, 4/14/2008

Spirometric Diagnosis

- Post-bronchodilator FEV_1/FVC measured 15 minutes after 400µg salbutamol or equivalent

- Obstructive Disease confirmed by post–bronchodilator $FEV_1/FVC < 0.7$

PFT Report

		Ref	Pre	% Ref	Post	% Ref	%Chg
Spirometry							
FVC	Liters	4.09	2.81	69	3.50	86	24
FEV1	Liters	3.30	1.00	30	1.08	33	8
FEV1/FVC	%	80	35		31		
FEF25-75%	L/sec	3.39	0.40	12	0.41	12	3
PEF	L/sec	8.21	2.62	32	2.74	33	5
Lung Volumes							
TLC	Liters	6.21	7.70	124			
VC	Liters	4.09	3.27	80			
FRC PL	Liters	3.17	5.42	171			
Vtg	Liters		7.01				
ERV	Liters		0.99				
RV	Liters	2.20	4.43	201			
RV/TLC	%	37	58				
Diffusing Capacity							
DLCO	mL/min/mmHg	25.2	12.9	51			
DL Adj	mL/min/mmHg	25.2	12.9	51			
DLCO/VA	1/min/mmHg	3.82	2.72	71			
DL/VA Adj	1/min/mmHg		2.72				
Resistance							
Raw	cmH2O/L/sec	1.46	4.87	333			
Gaw	L/sec/cmH2O	0.761	0.205	27			
sGaw	1/cmH2O sec	0.216	0.029	13			



200

Gold Grades

Severity of Airflow Obstruction

- GOLD 1: MILD

~FEV1 $\geq$ 80% predicted

- GOLD 2: MODERATE

~ 50% $\leq$ FEV1 < 80% predicted

- GOLD 3: SEVERE

~30%$\leq$ FEV1 < 50% Predicted

- GOLD 4: VERY SEVERE

~Very Severe FEV1 < 30% predicted

GOLD ABE Assessment Tool

Figure 2.10



2024 Teaching Slide Set

PRISm

- **COPD?**

PRISm

- **Preserved Ratio Impaired Spirometry**

Diseases Associated With Airflow Obstruction

- COPD
- Asthma
- Bronchiectasis
- Cystic Fibrosis
- Post-tuberculosis
- Lung cancer (greater risk in COPD)
- Obliterative Bronchiolitis

Chest Imaging

- X-Ray
- Low Dose Chest CT

Normal Chest X-Ray



Flattened Diaphragm



Chest CT

Blebs



Barrel Chest

"Blue Bloater"



Pink Puffer

Complications of COPD

- Pneumonia
- Respiratory Failure
- Cor Pulmonale
- Polycythemia
- Pneumothorax

Prevention Strategies
for Exacerbations

- **Avoid Triggers for exacerbations**

- **Create a COPD "Action Plan"**

~Green Zone, Yellow Zone, Red Zone

- **Healthy Lifestyle**

~ Staying active, eating healthy, managing stress

- **Vaccines (Pneumococcal, RSV, Pertussis, etc.)**

Treatment

- Patient and Family Education
- Smoking Cessation (if applicable)
- Pharmacological therapy
- Supplemental oxygen
- Valve Therapy
- Pulmonary Rehab

2024
Teaching
Slide Set

Goals for Treatment of Stable COPD

Figure 3.1



Management of COPD

Figure 3.2



2024 Teaching Slide Set

Pharmacology

Commonly Used Maintenance Medications in COPD*

Figure 3.18

Generic Drug Name	Inhaler Type	DELIVERY OPTIONS: Nebulizer	Oral	Injection	Duration of Action
BETA$_2$-Agonists					
Short-acting (SABA)					
Fenoterol	MDI	✓	pill, syrup		4-6 hours
Levalbuterol	MDI	✓			6-8 hours
Salbutamol (albuterol)	MDI & DPI	✓	pill, syrup, extended release tablet	✓	4-6 hours 12 hours (ext. release)
Terbutaline	DPI		pill	✓	4-6 hours
Long-acting (LABA)					
Arformoterol		✓			12 hours
Formoterol	DPI	✓			12 hours
Indacaterol	DPI				24 hours
Olodaterol	SMI				24 hours
Salmeterol	MDI & DPI				12 hours
Anticholinergics					
Short-acting (SAMA)					
Ipratropium bromide	MDI	✓			6-8 hours
Oxitropium bromide	MDI				7-9 hours
Long-acting (LAMA)					
Aclidinium bromide	DPI				MDI 12 hours
Glycopyrronium bromide	DPI		solution	✓	12-24 hours
Tiotropium	DPI, SMI, MDI				24 hours
Umeclidinium	DPI				24 hours
Glycopyrronium		✓			12 hours
Revefenacin		✓			24 hours
Combination Short-Acting Beta$_2$-Agonist Plus Anticholinergic in One Device (SABA+SAMA)					
Fenoterol/ipratropium	SMI	✓			6-8 hours
Salbutamol/ipratropium	SMI, MDI	✓			6-8 hours
Combination Long-Acting Beta$_2$-Agonist Plus Anticholinergic in One Device (LABA+LAMA)					
Formoterol/aclidinium	DPI				12 hours
Formoterol/glycopyrronium	MDI				12 hours
Indacaterol/glycopyrronium	DPI				12-24 hours
Vilanterol/umeclidinium	DPI				24 hours
Olodaterol/tiotropium	SMI				24 hours
Methylxanthines					
Aminophylline			solution	✓	Variable, up to 24 hours
Theophylline (SR)			pill	✓	Variable, up to 24 hours
Combination of Long-Acting Beta$_2$-Agonist Plus Corticosteroid in One Device (LABA+ICS)					
Formoterol/beclometasone	MDI, DPI				12 hours
Formoterol/budesonide	MDI, DPI				12 hours
Formoterol/mometasone	MDI				12 hours
Salmeterol/fluticasone propionate	MDI, DPI				12 hours
Vilanterol/fluticasone furoate	DPI				24 hours
Triple Combination in One Device (LABA+LAMA+ICS)					
Fluticasone/umeclidinium/vilanterol	DPI				24 hours
Beclometasone/formoterol/glycopyrronium	MDI, DPI				12 hours
Budesonide/formoterol/glycopyrrolate	MDI				12 hours
Phosphodiesterase-4 Inhibitors					
Roflumilast			pill		24 hours
Mucolytic Agents					
Erdosteine			pill		12 hours
Carbocysteine†			pill		
N-acetylcysteine†			pill		

*Not all formulations are available in all countries. In some countries other formulations and dosages may be available. †Dosing regimens are under discussion.
MDI = metered dose inhaler; DPI = dry powder inhaler; SMI = soft mist inhaler. Note that glycopyrrolate & glycopyrronium are the same compound.

Pharmacology

- Availability to the drug
- Cost of the drug to the patient
- Patients ability to administer the drug

~Dexterity, strength and cognition

Escalation of Care

Patient already using:
LABA or LAMA
LABA + LAMA
LABA + ICS
LABA + LAMA + ICS

Escalation of Care

Patient already using:
LABA + LAMA + ICS
Roflumilast
Azithromycin
Delete ICS

2024 Respiratory Treatments

Allergy & Asthma Network

800.878.4403 • AllergyAsthmaNetwork.org

Allergy & Asthma Network is a national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions through outreach, education, advocacy and research.

American College of Allergy, Asthma & Immunology

VIATRIS

Theravance Biopharma

DOSE INDICATOR
G = GENERIC AVAILABLE
N = NEBULIZER VIAL
DISEASE STATES:
A = ASTHMA
C = COPD

SHORT-ACTING BETA$_2$-AGONIST BRONCHODILATORS

relax tight muscles in airways and offer quick relief of symptoms such as coughing, wheezing and shortness of breath for 3-6 hours

- **Albuterol Sulfate Inhalation Solution** — 0.63, 1.5, 2.5 mg; 3 mL — G N
- **ProAir® Digihaler™** — 90 mcg — albuterol sulfate inhalation powder — DOSE A
- **ProAir RespiClick®** — 90 mcg — albuterol sulfate inhalation powder — DOSE A
- **Proventil® HFA** — 90 mcg — albuterol sulfate — DOSE A G
- **Ventolin® HFA** — 90 mcg — albuterol sulfate — DOSE A G
- **Xopenex®** — 0.31, 0.63, 1.25 mg; 3 mL — levalbuterol hydrochloride inhalation solution — A G N
- **Xopenex HFA®** — 45 mcg — levalbuterol tartrate — A G

LONG-ACTING BETA$_2$-AGONIST BRONCHODILATORS

relax tight muscles in airways and offer lasting relief of symptoms such as coughing, wheezing and shortness of breath for at least 12 hours

- **Brovana®** — 15 mg; 2 mL — arformoterol tartrate inhalation solution — C N
- **Perforomist®** — 20 mcg; 2 mL — formoterol fumarate inhalation solution — C N
- **Serevent® Diskus®** — 50 mcg — salmeterol xinafoate inhalation powder — DOSE A C
- **Striverdi® Respimat®** — 2.5 mcg — olodaterol hydrochloride — DOSE C

INHALED CORTICOSTEROIDS

reduce and prevent swelling of airway tissue; they do not relieve sudden symptoms of coughing, wheezing or shortness of breath

- **Alvesco® HFA** — 80, 160 mcg — ciclesonide — DOSE A
- **ArmonAir® Digihaler™** — 55, 113, 232 mcg — fluticasone propionate inhalation powder — DOSE A
- **Arnuity® Ellipta®** — 50, 100, 200 mcg — fluticasone furoate inhalation powder — DOSE A
- **Asmanex® HFA** — 50, 100, 200 mcg — mometasone furoate — DOSE A
- **Asmanex® Twisthaler®** — 110, 220 mcg — mometasone furoate inhalation powder — DOSE A
- **Fluticasone Propionate Diskus Inhalation Powder** — 50, 100, 250 mcg — Approved generic of Flovent Diskus — DOSE A
- **Fluticasone Propionate HFA** — 44, 110, 220 mcg — Approved generic of Flovent HFA — DOSE A
- **Pulmicort Flexhaler®** — 90, 180 mcg — budesonide inhalation powder — DOSE A
- **Pulmicort Respules®** — 0.25, 0.50, 1.0 mg; 2 mL — budesonide inhalation suspension — A G N
- **QVAR® Redihaler™** — 40, 80 mcg — beclomethasone dipropionate — DOSE A

MUSCARINIC ANTAGONISTS (ANTICHOLINERGIC)

relieve cough, sputum production, wheeze and chest tightness associated with chronic lung diseases

SHORT-ACTING

- **Atrovent® HFA** — 17 mcg — ipratropium bromide — DOSE C
- **Ipratropium Bromide Inhalation Solution** — 0.5, 2.5 mg; 2.5 mL — C G N

LONG-ACTING

- **Incruse™ Ellipta®** — 62.5 mcg — umeclidinium inhalation powder — DOSE C
- **Spiriva® HandiHaler®** — 18 mcg — tiotropium bromide inhalation powder — C
- **Spiriva® Respimat®** — 1.25, 2.5 mcg — tiotropium bromide — DOSE A C
- **Tudorza™ Pressair™** — 400 mcg — aclidinium bromide inhalation powder — DOSE C
- **Yupelri®** — 175 mcg, 3 mL — revefenacin inhalation solution — C N

PDE4 INHIBITORS

target lung inflammation and reduce exacerbations

- **Daliresp®** — 250, 500 mcg — roflumilast — C

COMBINATION MEDICATIONS

contain both inhaled corticosteroid and long-acting beta$_2$-agonist (LABA)

- **Advair Diskus®** — 100/50, 250/50, 500/50 mcg — fluticasone propionate and salmeterol inhalation powder — DOSE A C G
- **Advair® HFA** — 45/21, 115/21, 230/21 mcg — fluticasone propionate and salmeterol xinafoate — DOSE A G
- **AirDuo® Digihaler™** — 55/14, 113/14, 232/14 mcg — fluticasone propionate and salmeterol inhalation powder — DOSE A
- **AirDuo® RespiClick®** — 55/14, 113/14, 232/14 mcg — fluticasone propionate and salmeterol inhalation powder — DOSE A G
- **Breo® Ellipta®** — 50/25, 100/25, 200/25 mcg — fluticasone furoate and vilanterol inhalation powder — DOSE A C G
- **Breyna™** — 80/4.5, 160/45 mcg — budesonide and formoterol fumarate dihydrate (approved generic of Symbicort) — DOSE A C
- **Dulera®** — 50/5, 100/5, 200/5 mcg — mometasone furoate and formoterol fumarate dihydrate — DOSE A
- **Symbicort®** — 80/4.5, 160/4.5 mcg — budesonide and formoterol fumarate dihydrate — DOSE A C G
- **Wixela™ Inhub™** — 100/50, 250/50, 500/50 mcg — fluticasone propionate and salmeterol xinafoate (approved generic of Advair Diskus) — DOSE A C

contain both long-acting beta$_2$-agonist (LABA) and long-acting muscarinic antagonist (LAMA)

- **Anoro® Ellipta®** — 62.5/25 mcg — umeclidinium and vilanterol inhalation powder — DOSE C
- **Bevespi Aerosphere®** — 9/4.8 mcg — glycopyrrolate and formoterol fumarate — DOSE C
- **DuaKlir® Pressair®** — 400, 12 mcg — aclidinium bromide and formoterol fumarate — DOSE C
- **Stiolto™ Respimat®** — 2.5/2.5 mcg — tiotropium bromide and olodaterol — DOSE C

contain inhaled corticosteroid, long-acting beta$_2$-agonist (LABA) and long-acting muscarinic antagonist (LAMA)

- **Trelegy® Ellipta®** — 200/62.5/25 mcg, 100/62.5/25 mcg — fluticasone furoate, umeclidinium and vilanterol inhalation powder — DOSE A C
- **Breztri Aerosphere™** — 160/9/4.8 mcg — budesonide, glycopyrrolate and formoterol fumarate — DOSE C

contain both short-acting beta$_2$-agonist and short-acting muscarinic antagonist

- **Combivent® Respimat®** — 20/100 mcg — ipratropium bromide and albuterol — DOSE C
- **Ipratropium Bromide and Albuterol Sulfate Inhalation Solution** — 2.5 mg; 3 mL — C G

contain inhaled corticosteroid and short-acting beta$_2$-agonist (SABA)

- **AirSupra®** — 80, 90 mcg — budesonide and albuterol — DOSE A

BIOLOGICS

target cells and pathways that cause airway inflammation; delivered by injection or IV

- **Cinqair®** — 62.5/25 ml — reslizumab — A
- **Dupixent®** — 100, 200, 300 mg — dupilumab — A
- **Fasenra™** — 30 mg — benralizumab — A
- **Nucala®** — 100 mg — mepolizumab — A
- **Tezspire™** — 210 mg — tezepelumab-ekko — A
- **Xolair®** — 75 to 375 mg — omalizumab — A

LEUKOTRIENE MODIFIERS

block chemicals called leukotrienes that cause airway inflammation; available as tablet or granules

- **Singulair®** — 4, 5, 10 mg — montelukast — A
- **Zafirlukast** — 10, 20 mg — zafirlukast — A
- **Zyflo CR®** — 600 mg — zileuton — A

Reviewed by Dennis Williams, PharmD

Generic versions of some brand name inhalers are not included on this poster. Generic inhalers may be a different color.

Zephyr® Valve

Zephyr Valve, image courtesy of Pulmonx Corp.

Lung Surgery

- **Bullectomy**
- **LVRS**
- **Lung Transplant**

Exacerbation

Exacerbation

ABG

- PH 7.19
- PaCO2 75 mmHg
- PaO2 52 mmHg
- HCO3- 30 mEq/L

NIV

V60 Modes



CPAP
BIPAP
AVAPS
PCV

Intubation

Extubation

Pulmonary Rehab

- Breathing exercises
- Education
- Phycological Counseling
- Exercise Training
- Nutrition counseling

Smoking

1-800-QUIT-NOW

Homecare

Home oxygen	Home ventilation
• Group I • Group II	• R/O OSA with CPAP

Resources
COPD Foundation App



Resources
COPD
GOLD App



Resources ATS Guidelines Booklet



Suggested Courses

- Average Volume-Assured Pressure Support Treatment in COPD
- COPD Management: Educating Patients on More Than Medication
- Understanding COPD GOLD Guidelines & 2024 Updates

Alyssa Dittner, BSRT, RRT, PDE, TTS

Suggested Courses

- The Latest GOLD COPD Guidelines (With Cases to Ponder)
- A Refresher on Pulmonary Functions Testing Concepts & Interpretation

Tim W. Gilmore, PhD, RRT, RRT-NPS, RRT-ACCS, CPFT, AE-C

Summary & Review



References

- https://goldcopd.org/2024-gold-report/
- https://www.ncbi.nlm.nih.gov/books/NBK482437/
- https://www.thoracic.org/statements/copd.php
- https://www.chestnet.org/guidelines-and-topic-collections/topic-collections/infographics/escalating-therapy-in-patients-with-copd-experiencing-exacerbationshttps://www.thoracic.org/statements/guideline-implementation-tools/pharmacologic-mgmt-of-copd.php
- https://www.uofmhealth.org/conditions-treatments/pulmonary/zephyr-valve-treatment-copd-emphysema
- https://allergyasthmanetwork.org/news/inhalers-at-a-glance-posters-resources/